Bristol Myers lifts outlook as Eliquis drives Q2 earnings beat
US pharma major Bristol Myers Squibb (NYSE: BMY) has raised its full-year outlook after second-quarter 2026 revenue and earnings came in well above analyst expectations, helped by strong demand for Eliquis (apixaban) and continued growth from newer medicines.
Revenue rose 6%, or 5% excluding currency movements, to $12.97 billion, compared with analyst expectations of around $11.74 billion. Net income more than doubled to $3.32 billion from $1.31 billion a year earlier, while GAAP earnings per share (EPS) increased to $1.62 from $0.64. Adjusted EPS rose 40% to $2.04, ahead of the consensus forecast of about $1.60.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze